South Korea Daily Briefing

SK Hynix filed with the SEC that HYAICO Corporation — its US-incorporated AI investment subsidiary — will be chaired by SK Group Chairman Chey Tae-won, with SK Hynix President Song Hyun-jong as CEO. This is the most consequential Korea market story of the week: a chaebol chairman personally chairing a US AI investment entity signals that SK Hynix is structurally committed to the AI memory cycle beyond any single customer or regulatory cycle. HYAICO's mandate will be to invest in US AI infrastructure — the same ecosystem (Nvidia, Hyperscalers, AI server ODMs) that generates demand for SK Hynix's HBM3E and HBM4 roadmap. A Democrat-controlled Congress may slow OpenAI's growth pace, but Microsoft, AWS, and Google's AI infrastructure spend is multi-year and largely policy-agnostic — and those are HYAICO's targets.

Korea's Fair Trade Commission scheduled its full board review of the Naver-Dunamu (Kakao/Upbit parent) merger for November 18 — approximately one year after the combination was first filed, covering over 10 related markets including crypto exchange, fintech, and digital payment. A ruling is expected within 1-2 weeks of the full board hearing, meaning November end is the binary event date. If approved, the merger creates Korea's dominant fintech and digital-asset broker combination: Naver Financial's payment processing scale plus Dunamu's Upbit crypto exchange position. If blocked or conditioned, Dunamu's digital-asset licensing strategy for 2027 is restructured. The KRX has been watching for any chaebol-governance signal from the FTC — a precedent-setting ruling here affects how regulators view future horizontal fintech M&A.

Samsung BioLogics' union confirmed a second strike beginning November 6, with approximately 400 workers (around 10% of union membership) from QA testing and QA departments walking out after wage and HR reform negotiations collapsed. The key operational risk is regulatory: QC testing and quality assurance are the GMP-critical functions in CDMO manufacturing — any slowdown in batch testing at the Incheon facility creates the risk of delayed API and finished-goods releases for multinational pharma clients. Samsung Bio has contracts with over 60 global pharma companies; a prolonged QA walkout triggers force majeure clauses that allow clients to invoke penalties or shift production allocations. The first strike did not trigger material production disruptions, but the second strike with QA/QC specifically targeted is a qualitative escalation.